Curcumin için Ulcerative Colitis (UC)
BMulticenter RCT (CUBE trial) showed curcumin (2 g/day) plus mesalamine maintained remission better than mesalamine alone. Reduced relapse rate from 20% to 5% over 12 months.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dcurcumin\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Sonuç
Multicenter RCT (CUBE trial) showed curcumin (2 g/day) plus mesalamine maintained remission better than mesalamine alone. Reduced relapse rate from 20% to 5% over 12 months.
Key Study Findings
Systematic Review
The Complementary and Alternative Roles of Curcumin in Treatment of Ulcerative Colitis: An Umbrella Review.
Dose: None
vs: placebo or standard therapy
Outcome: ulcerative colitis outcomes (18 outcomes across 7 SR/MAs)
Etki: None
None
Popülasyon: patients with ulcerative colitis
Other
Reactive Oxygen Species-Responsive Polymer Drug Delivery System Targeted Oxidative Stressed Colon Cells to Ameliorate Colitis.
Dose: None
vs: untreated colitis controls
Outcome: mitigation of colitis symptoms (ROS scavenging, barrier restoration, …
Etki: None
None
Popülasyon: UC animal model and oxidatively stressed colon cells
Review
Therapeutic potential and underlying mechanisms of phytoconstituents: emphasizing on resveratol, curcumin, quercetin, berberine, and hesperidin …
Dose: None
vs: None
Outcome: None
Etki: None
None
Popülasyon: None
Systematic Review
Curcumin and multiple health outcomes: critical umbrella review of intervention meta-analyses.
Dose: None
vs: Various comparators
Outcome: Multiple health outcomes
Etki: None
None
Popülasyon: Human subjects across 25 meta-analyses
Review
Natural products for the treatment of ulcerative colitis: focus on the JAK/STAT pathway.
Dose: None
vs: None
Outcome: None
Etki: None
None
Popülasyon: None
In Vitro
Curcumin attenuates ulcerative colitis via regulation of Sphingosine kinases 1/NF-κB signaling pathway.
Dose: None
vs: DSS-induced UC mice
Outcome: UC inflammation via SphK1/NF-kB pathway
Etki: None
None
Popülasyon: DSS-induced UC murine model
Key Statistics
5
Çalışmalar
400
Katılımcılar
↑
Positive
B
Derece
Referenced Papers
The Complementary and Alternative Roles of Curcumin in Treatment of Ulcerative Colitis: An Umbrella Review.
Systematic Review
Nutrition reviews
2026
ACS nano
2025
29 atıf
Frontiers in immunology
2025
20 atıf
Naunyn-Schmiedeberg's archives of …
2025
14 atıf
Curcumin and multiple health outcomes: critical umbrella review of intervention meta-analyses.
Systematic Review
Frontiers in pharmacology
2025
10 atıf
BioFactors (Oxford, England)
2025
9 atıf
Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.
Systematic Review
Frontiers in nutrition
2025
8 atıf
European journal of …
2025
7 atıf
Explore (New York, …
2025
5 atıf
Journal of agricultural …
2025
3 atıf
Materials today. Bio
2025
3 atıf
Frontiers in nutrition
2025
2 atıf
Frontiers in pharmacology
2025
1 atıf
Cellular and molecular …
2025
Nutrients
2025
International journal of …
2025
Clinical gastroenterology and …
2024
52 atıf
Food research international …
2024
44 atıf
Advanced materials (Deerfield …
2024
37 atıf
Journal of pharmaceutical …
2024
29 atıf
International journal of …
2024
27 atıf
Nutrients
2024
23 atıf
ACS omega
2024
16 atıf
Frontiers in pediatrics
2024
4 atıf
[Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review].
Systematic Review
Zeitschrift fur Gastroenterologie
2024
3 atıf
World journal of …
2024
Frontiers in endocrinology
2023
253 atıf
Metabolites
2023
134 atıf
Advanced science (Weinheim, …
2023
90 atıf
Journal of nanobiotechnology
2023
63 atıf
Pharmaceuticals (Basel, Switzerland)
2023
18 atıf
Toxicology mechanisms and …
2023
5 atıf
Journal of nanobiotechnology
2022
206 atıf
International journal of …
2022
142 atıf
The American journal …
2022
86 atıf
Frontiers in immunology
2022
68 atıf
Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis.
Meta-Analysis
Journal of ethnopharmacology
2022
39 atıf
American family physician
2022
38 atıf
Nutrients
2022
19 atıf
Turkish journal of …
2022
3 atıf
Advances in experimental …
2021
87 atıf
Molecules (Basel, Switzerland)
2021
85 atıf
Effects of the Use of Curcumin on Ulcerative Colitis and Crohn's Disease: A Systematic Review.
Meta-Analysis
Journal of medicinal …
2021
52 atıf
European journal of …
2021
40 atıf
Complementary therapies in …
2021
30 atıf
A Systematic Review of the Clinical Use of Curcumin for the Management of Gastrointestinal Diseases.
Systematic Review
Advances in experimental …
2021
8 atıf
Clinical gastroenterology and …
2020
49 atıf
The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.
Systematic Review
Nutrients
2020
48 atıf
Nutrients
2020
30 atıf
Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta-analysis of randomized controlled trials.
Meta-Analysis
Journal of gastroenterology …
2020
30 atıf
Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis.
Meta-Analysis
Expert review of …
2020
25 atıf
Therapeutic advances in …
2020
21 atıf
Medicine
2020
4 atıf
International journal of …
2019
137 atıf
Nutrients
2019
71 atıf
Critical reviews in …
2019
48 atıf
Journal of medicinal …
2019
17 atıf
Immunopharmacology and immunotoxicology
2018
96 atıf
Gastroenterology clinics of …
2018
67 atıf
Nutrients
2018
46 atıf
Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis.
Meta-Analysis
The American journal …
2018
30 atıf
Medical principles and …
2017
45 atıf
Acta medica Indonesiana
2017
24 atıf
The Medical clinics …
2017
9 atıf
Ugeskrift for laeger
2017
Annals of gastroenterology
2016
41 atıf
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
Review
Current pharmaceutical design
2016
32 atıf
Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases.
Systematic Review
Journal of Crohn's …
2015
184 atıf
Annals of gastroenterology
2015
135 atıf
Molecules (Basel, Switzerland)
2014
122 atıf
World journal of …
2014
23 atıf
The AAPS journal
2013
1866 atıf
Alimentary pharmacology & …
2013
128 atıf
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Other
Journal of pediatric …
2013
103 atıf
Food & function
2012
151 atıf
Revista de gastroenterologia …
2008
2 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 500-1,500 mg/day with piperine (black pepper extract) for absorption
- ibssupport:
- 500-1,000 mg/day
- ucmaintenance:
- 2,000 mg/day (1 g twice daily) as adjunct to mesalamine
Üst sınır: Well-tolerated up to 8 g/day in clinical trials (most studies use 1-2 g/day)
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| Varying dosages | -- | Positive | -- |
| None | -- | Positive | -- |
En iyi alım zamanı: With meals containing fat and black pepper for enhanced absorption
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ GI discomfort (nausea, diarrhea, abdominal pain) at high doses
- ⚠ Yellow staining of skin/teeth with topical/oral contact
- ⚠ Increased gallbladder contractions (avoid with gallstones or bile duct obstruction)
- ⚠ Iron chelation (may reduce iron absorption at very high doses)
Bilinen Etkileşimler
- ● Anticoagulants (curcumin has antiplatelet properties; may increase bleeding risk)
- ● Chemotherapy agents (curcumin may alter drug metabolism via CYP enzyme inhibition)
- ● Sulfasalazine (additive anti-inflammatory effect — may be beneficial in IBD)
- ● Iron supplements (curcumin may chelate iron; space dosing)
- ● Piperine/black pepper (enhances curcumin bioavailability by 2,000% — commonly co-administered)
Tolere edilebilir üst alım: Well-tolerated up to 8 g/day in clinical trials (most studies use 1-2 g/day)
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does Curcumin help with Ulcerative Colitis (UC)?
Based on 5 studies with 400 participants, there is moderate evidence from clinical studies that Curcumin may support Ulcerative Colitis (UC) management. Our evidence grade is B (Good Evidence).
How much Curcumin should I take for Ulcerative Colitis (UC)?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day with piperine (black pepper extract) for absorption. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Curcumin?
Reported side effects may include GI discomfort (nausea, diarrhea, abdominal pain) at high doses, Yellow staining of skin/teeth with topical/oral contact, Increased gallbladder contractions (avoid with gallstones or bile duct obstruction), Iron chelation (may reduce iron absorption at very high doses). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Curcumin and Ulcerative Colitis (UC)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 5 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Ulcerative Colitis (UC)
Curcumin diğer sağlık durumları için
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.